ATE492542T1 - Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas - Google Patents

Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas

Info

Publication number
ATE492542T1
ATE492542T1 AT05812611T AT05812611T ATE492542T1 AT E492542 T1 ATE492542 T1 AT E492542T1 AT 05812611 T AT05812611 T AT 05812611T AT 05812611 T AT05812611 T AT 05812611T AT E492542 T1 ATE492542 T1 AT E492542T1
Authority
AT
Austria
Prior art keywords
biphenyl
carbonylaminosic
obesitas
preparation
treatment
Prior art date
Application number
AT05812611T
Other languages
English (en)
Inventor
Roger Smith
Stephen O'connor
Philip Coish
Derek Lowe
Roger Clark
Jeffrey Stebbins
Ann-Marie Campbell
Christiana Akuche
Tatiana Shelekhin
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of ATE492542T1 publication Critical patent/ATE492542T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05812611T 2004-10-15 2005-10-14 Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas ATE492542T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61897504P 2004-10-15 2004-10-15
PCT/US2005/037215 WO2006044775A2 (en) 2004-10-15 2005-10-14 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity

Publications (1)

Publication Number Publication Date
ATE492542T1 true ATE492542T1 (de) 2011-01-15

Family

ID=36203612

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05812611T ATE492542T1 (de) 2004-10-15 2005-10-14 Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas

Country Status (21)

Country Link
US (2) US7759376B2 (de)
EP (1) EP1805156B1 (de)
JP (1) JP2008516978A (de)
KR (1) KR20070063546A (de)
CN (1) CN101087769A (de)
AT (1) ATE492542T1 (de)
AU (1) AU2005295453A1 (de)
BR (1) BRPI0516483A (de)
CA (1) CA2583784A1 (de)
CR (1) CR9034A (de)
DE (1) DE602005025517D1 (de)
EA (1) EA200700851A1 (de)
EC (1) ECSP077397A (de)
ES (1) ES2357015T3 (de)
IL (1) IL182218A0 (de)
MA (1) MA28935B1 (de)
MX (1) MX2007004217A (de)
NO (1) NO20072461L (de)
TN (1) TNSN07111A1 (de)
WO (1) WO2006044775A2 (de)
ZA (1) ZA200703002B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
EP2418202B1 (de) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivate als DGAT- Inhibitoren
CN101460470B (zh) 2006-05-30 2011-05-18 阿斯利康(瑞典)有限公司 作为dgat1抑制剂的1,3,4-二唑衍生物
MX2008015228A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
ES2536406T3 (es) 2007-06-08 2015-05-25 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2152271B1 (de) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidin-/piperazinderivate
JP5464709B2 (ja) * 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
NZ586104A (en) 2007-12-20 2012-02-24 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
PT2303270T (pt) 2008-05-05 2017-08-25 Sanofi Sa Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
UY32349A (es) * 2008-12-23 2010-07-30 Novartis Ag Derivados de biaril-bencil-amina
US20110319396A1 (en) * 2009-01-23 2011-12-29 Msd K.K. Benzodiazepin-2-on derivatives
EP2805951B1 (de) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitoren von Diacylglycerin-O-acyltransferase 1 (DGAT-1) und Verwendungen davon
US8268820B2 (en) 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
TW201103895A (en) 2009-06-19 2011-02-01 Astrazeneca Ab Chemical compounds
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
NZ599855A (en) 2009-11-05 2014-06-27 Piramal Entpr Ltd Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity
JP5746977B2 (ja) * 2009-12-16 2015-07-08 ポーラ化成工業株式会社 色素沈着予防又は改善剤
NZ602125A (en) 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
KR101392334B1 (ko) 2011-05-03 2014-05-12 한국생명공학연구원 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2892896B1 (de) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
ES2828704T3 (es) * 2014-08-01 2021-05-27 Bayer Pharma AG Procedimiento para la preparación de (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida y su purificación para su uso como principio activo farmacéutico
CN105646510A (zh) * 2014-12-02 2016-06-08 重庆宁牧生态农业有限公司 一种用作抗肥胖剂的化合物
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора
CA3141405A1 (en) * 2019-06-12 2020-12-17 H. Charles Manning Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) * 2020-10-19 2021-02-09 济南大学 一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) * 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

Also Published As

Publication number Publication date
CN101087769A (zh) 2007-12-12
BRPI0516483A (pt) 2008-09-02
WO2006044775A3 (en) 2006-06-15
US20110118302A1 (en) 2011-05-19
NO20072461L (no) 2007-07-03
WO2006044775A2 (en) 2006-04-27
IL182218A0 (en) 2007-09-20
ES2357015T3 (es) 2011-04-15
US7759376B2 (en) 2010-07-20
TNSN07111A1 (en) 2008-06-02
DE602005025517D1 (de) 2011-02-03
JP2008516978A (ja) 2008-05-22
US20070265298A1 (en) 2007-11-15
ECSP077397A (es) 2007-05-30
EP1805156A4 (de) 2009-06-10
KR20070063546A (ko) 2007-06-19
MA28935B1 (fr) 2007-10-01
ZA200703002B (en) 2008-08-27
AU2005295453A1 (en) 2006-04-27
MX2007004217A (es) 2007-06-11
CA2583784A1 (en) 2006-04-27
EA200700851A1 (ru) 2007-12-28
EP1805156B1 (de) 2010-12-22
EP1805156A2 (de) 2007-07-11
CR9034A (es) 2008-11-18

Similar Documents

Publication Publication Date Title
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
DE602005018366D1 (de) Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE60322983D1 (de) Pflanzliche zusammensetzung zur behandlung von gastrointestinalen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties